Prognostic and clinical value of Sirt1 expression in gastric cancer: A systematic meta-analysis

Abstract

Many studies have reported that the expression of silent information regulator 1 (Sirt1) is associated with the clinical features and prognosis of patients with gastric cancer, but the exact function remains controversial. We conducted this study to illustrate the clinical and prognostic value of Sirt1 in gastric cancer. The related publications before December 2015 were searched in the databases including Pubmed, Cochrane Library, Embase and China National Knowledge Infrastructure (CNKI). The studies were included and excluded according to the inclusion criteria and exclusion criteria. The 3- and 5-year overall survival (OS) and clinical features such as age, T stage, N stage and differentiation were analyzed by software RevMan 5.3. A total of 1650 patients in 7 studies were included according to the inclusion criteria and exclusion criteria. The high expression of Sirt1 was found in 58.4% cases by immunohistochemistry. High expression of Sirt1 was closely linked with the 3-year OS (OR=0.25, 95% CI: 0.16–0.39, P<0.00001, fixed), patient’s age (≥60 years old vs. <60 years old; OR=1.43, 95% CI: 1.06–1.93, P=0.02, fixed), T stage (T3+T4 vs. T1+T2; OR=1.45, 95% CI: 1.08–1.94, P=0.01, fixed), N stage (N1+N2+N3 vs. N0; OR=3.47, 95% CI: 2.39–5.05, P<0.00001, fixed) and tumor differentiation (G1+G2 vs. G3; OR=0.50, 95% CI: 0.35–0.69, P<0.0001, fixed). Nevertheless, it seemed that high expression of Sirt1 was not associated with 5-year OS (OR=0.44, 95% CI: 0.15–1.28, P=0.13, random). It was suggested that the high expression of Sirt1 implies a poor prognosis of gastric cancer patients in a relatively short period (3 years), but not in a long time (≥5 years). The expression of Sirt1 is also linked with patients’ age, T stage, N stage and tumor differentiation.

Keywords

gastric cancer / silent information regulator 1 / clinicopathological characteristics / prognosis

References

[1] TorreLA, BrayF, SiegelRL, et al. . Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2): 87-108 PMID: 25651787

[2] PiazueloMB, CorreaP. Gastric cáncer: Overview. Colomb Med (Cali), 2013, 44(3): 192-201

[3] YuanH, SuL, ChenWY. The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Onco Targets Ther, 2013, 6(1): 1399-1416 PMID: 24133372 PMCID: 3797239

[4] PetersCJ, ReesJR, HardwickRH, et al. . A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology, 2010, 139(6): 1995-2004 PMID: 20621683

[5] FinleyLW, CarracedoA, LeeJ, et al. . SIRT3 opposes reprogramming of cancer cell metabolism through HIF1a destabilization. Cancer Cell, 2011, 19(3): 416-428 PMID: 21397863 PMCID: 3065720

[6] TannoM, SakamotoJ M T, et al. . Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J Biol Chem, 2007, 282(9): 6823-6832 PMID: 17197703

[7] LiuT, LiuPY, MarshallGM. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res, 2009, 69(5): 1702-1705 PMID: 19244112

[8] WuM, WeiW, XiaoX, et al. . Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Med Oncol, 2012, 29(5): 3240-3249 PMID: 22661383

[9] MenssenA, HydbringP, KapelleK, et al. . The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad Sci USA, 2012, 109(4): E187-196 PMID: 22190494 PMCID: 3268300

[10] KojimaK, OhhashiR, FujitaY, et al. . A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem Biophys Res Commun, 2008, 373(3): 423-428 PMID: 18573234

[11] ChaEJ, NohSJ, KwonKS, et al. . Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res, 2009, 15(13): 4453-4459 PMID: 19509139

[12] NoguchiA, KikuchiK, ZhengH, et al. . SIRT1 expression is associated with a poor prognosis, whereas DBC1 is associated with favorable outcomes in gastric cancer. Cancer Med, 2014, 3(6): 1553-1561 PMID: 25146318 PMCID: 4298382

[13] FengAN, ZhangLH, FanXS, et al. . Expression of SIRT1 in gastric cardiac cancer and its clinicopathologic significance. Int J Surg Pathol, 2011, 19(6): 743-750 PMID: 21865267

[14] KangY, JungWY, LeeH, et al. . Expression of SIRT1 and DBC1 in gastric adenocarcinoma. Korean J Pathol, 2012, 46(6): 523-531 PMID: 23323102 PMCID: 3540329

[15] ZhangLH, HuangQ, FanXS, et al. . Clinicopathological significance of SIRT1 and p300/CBP expression in gastroesophageal junction (GEJ) cancer and the correlation with E-cadherin and MLH1. Pathol Res Pract, 2013, 209(10): 611-617 PMID: 24035280

[16] LinF, ChenR, ZhaoW, et al. . Expression and clinical significance of Sirt1, P53 and P-gp in gastric carcinoma. J Xi’an Jiaotong Univ (Med Sci), 2013, 34(5): 642-647

[17] ZhangB, WangJT, MinJ, et al. . Expression of Sirt1 and P55PIK in gastric cancer and clinical significance. Acta Med Univ Sci Technol Huazhong (Chinese), 2012, 41(6): 735-739

[18] ImaiS, ArmstrongCM, KaeberleinM, et al. . Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature, 2000, 403(6771): 795-800 PMID: 10693811

[19] LiY, YokotaT, GamaV, et al. . Bax-inhibiting peptide protects cells from polyglutamine toxicity caused by Ku70 acetylation. Cell Death Differ, 2007, 14(12): 2058-2067 PMID: 17885668

[20] HanMK, SongEK, GuoY, et al. . SIRT1 regulates apoptosis and Nanog expression in mouse embryonic stem cells by controlling p53 subcellular localization. Cell Stem Cell, 2008, 2(3): 241-251 PMID: 18371449 PMCID: 2819008

[21] BrunetA, SweeneyLB, SturgillJF, et al. . Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science, 2004, 303(5666): 2011-2015 PMID: 14976264

[22] HiraikeH, Wada-HiraikeO, NakagawaS, et al. . Expression of DBC1 is associated with nuclear grade and HER2 expression in breast cancer. Exp Ther Med, 2011, 2(6): 1105-1109 PMID: 22977628 PMCID: 3440794

[23] LeeH, KimKR, NohSJ, et al. . Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol, 2011, 42(2): 204-213 PMID: 21056897

[24] BylesV, ZhuL, LovaasJD, et al. . SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene, 2012, 31(43): 4619-4629 PMID: 22249256 PMCID: 4157820

[25] KrieglL, ViethM, KirchnerT, et al. . Up-regulation of c-MYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer. Oncotarget, 2012, 3(10): 1182-1193 PMID: 23045412 PMCID: 3717960

[26] ChenHC, JengYM, YuanRH, et al. . SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis. Ann Surg Oncol, 2012, 19(6): 2011-2019 PMID: 22146883

[27] HerranzD, Munoz-MartinM, CanameroM, et al. . Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun, 2010, 1(1): 3 PMID: 20975665 PMCID: 3641391

[28] FiresteinR, BlanderG, MichanS, et al. . The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One, 2008, 3(4): e2020 PMID: 18414679 PMCID: 2289879

[29] KabraN, LiZ, ChenL, et al. . SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem, 2009, 284(27): 18 210-18 217

[30] NoguchiA, LiX, KubotaA, et al. . SIRT1 expression is associated with good prognosis for head and neck squamous cell carcinoma patients. Oral Surg Oral Med Oral Pathol Oral Radiol, 2013, 115(3): 385-392 PMID: 23453030